Adocia
Adocia is a clinical-stage biotechnology company specialized in the development of innovative treatments for diabetes and obesity. Since its inception in 2005, it has built expertise in these metabolic diseases, focusing on innovative formulations of insulins and hormones, and has a diversified pipeline of specialty products. The company aims to improve treatments and bring medical benefits to patients worldwide, leveraging disruptive technologies and strategic licensing agreements.
Industries
Nr. of Employees
medium (51-250)
Adocia
115 Avenue Lacassagne, 69003 Lyon, France
Patents
Compositions in the form of an injectable aqueous solution comprising amylin, an amylin agonist receptor or an amylin analogue and a co-polyamino acid
US-12186373-B2
View DetailsInjectable pH 7 solution comprising at least one basal insulin having a pI from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
US-11883496-B2
View DetailsCompositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid
US-11707507-B2
View DetailsInjectable solution at pH 7 comprising at least one basal insulin wherein the pI is comprised from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
US-11633460-B2
View Details
Compositions in the form of an injectable aqueous solution comprising amylin, an amylin agonist receptor or an amylin analogue and a co-polyamino acid
US-12186373-B2
View DetailsInjectable pH 7 solution comprising at least one basal insulin having a pI from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
US-11883496-B2
View DetailsCompositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid
US-11707507-B2
View DetailsInjectable solution at pH 7 comprising at least one basal insulin wherein the pI is comprised from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
US-11633460-B2
View DetailsProducts
Ultra-rapid insulin formulation (ultra-rapid lispro, clinical-stage)
An ultra-rapid-acting insulin formulation designed to provide tighter glycemic control compared with standard insulin formulations; developed through a protein formulation platform and advanced to late-stage clinical testing.
Immunoprotective scaffold for islet cell therapy (implantable cell-therapy scaffold)
An implantable biomaterial scaffold designed to provide immunoprotection and support for pancreatic islet cells, with translational data from human islets to stem-cell derived islets.
Combination hormone formulations for diabetes and obesity
Proprietary formulations combining metabolic hormones intended to address interlinked metabolic diseases (diabetes and obesity).
Oral peptide delivery formulations (oral peptide platform)
Formulation approaches aimed at enabling oral administration of peptide drugs as an alternative to injectable delivery.
Ultra-rapid insulin formulation (ultra-rapid lispro, clinical-stage)
An ultra-rapid-acting insulin formulation designed to provide tighter glycemic control compared with standard insulin formulations; developed through a protein formulation platform and advanced to late-stage clinical testing.
Immunoprotective scaffold for islet cell therapy (implantable cell-therapy scaffold)
An implantable biomaterial scaffold designed to provide immunoprotection and support for pancreatic islet cells, with translational data from human islets to stem-cell derived islets.
Combination hormone formulations for diabetes and obesity
Proprietary formulations combining metabolic hormones intended to address interlinked metabolic diseases (diabetes and obesity).
Oral peptide delivery formulations (oral peptide platform)
Formulation approaches aimed at enabling oral administration of peptide drugs as an alternative to injectable delivery.
Services
Out-licensing and co-development of proprietary technologies and products after demonstration of human proof-of-concept; structuring commercial and development agreements with pharmaceutical partners.
Execution of clinical programs and translational research to move product candidates from preclinical stages through human proof-of-concept, enabling subsequent licensing or co-development.
Out-licensing and co-development of proprietary technologies and products after demonstration of human proof-of-concept; structuring commercial and development agreements with pharmaceutical partners.
Execution of clinical programs and translational research to move product candidates from preclinical stages through human proof-of-concept, enabling subsequent licensing or co-development.
Expertise Areas
- Clinical trial management (Phase 1–3)
- Formulation development for therapeutic proteins and peptides
- Cell therapy scaffold development and translational scale-up
- Oral peptide delivery
Key Technologies
- Protein and peptide formulation technologies
- Injectable sustained-release platforms
- Immunoprotective biomaterial scaffolds for cell therapy
- Oral peptide delivery platforms